A5079880822- Cardiomyopathy and Myosin Studies
- Cardiovascular Effects of Exercise
- Cardiovascular Function and Risk Factors
- Cardiac Structural Anomalies and Repair
- Inflammasome and immune disorders
- Cardiovascular Disease and Adiposity
- Long-Term Effects of COVID-19
- COVID-19 Clinical Research Studies
- Viral Infections and Immunology Research
Cleveland Clinic
2021-2024
Center for Clinical Research (United States)
2022-2024
Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but associated morbidity and mortality. This study sought to determine whether the oral myosin inhibitor mavacamten enables improve sufficiently no longer meet guideline criteria choose not undergo SRT. Patients left ventricular (LV) outflow tract (LVOT) gradient ≥50 mm Hg at...
In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated respiratory failure and death. We aimed to evaluate whether mavrilimumab, monoclonal antibody GM-CSF receptor, would improve outcomes in COVID-19 pneumonia systemic hyperinflammation.This investigator-initiated, multicentre, double-blind, randomised trial was done at seven hospitals USA. Inclusion required hospitalisation, pneumonia,...
Septal reduction therapy (SRT) in patients with intractable symptoms from obstructive hypertrophic cardiomyopathy (oHCM) is associated variable morbidity and mortality. The VALOR-HCM trial (A Study to Evaluate Mavacamten Adults Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Reduction Therapy) examined the effect of mavacamten on need SRT through week 32 oHCM.A double-blind randomized placebo-controlled multicenter at 19 US sites included oHCM maximal tolerated...
Introduction: The performance of automated left ventricular ejection fraction (LVEF) assessment in patients with altered cardiac chamber geometry, such as those obstructive hypertrophic cardiomyopathy (HCM), is not well described. Aims: Accurate LVEF required for dose titration and continuation myosin inhibitors HCM. From the VALOR-HCM trial (NCT04349072), agreement two commercially available software packages was compared blinded core lab LVEF. Methods: baseline week 16, among 112...